Literature DB >> 18261494

Abnormalities in glucose metabolism in patients with schizophrenia treated with atypical antipsychotic medications.

Alan N Elias1, Heather Hofflich.   

Abstract

The incidence of carbohydrate intolerance and overt diabetes is increased in patients with schizophrenia treated with the newer atypical antipsychotic agents. The precise mechanism for these abnormalities remains obscure. This review examines the potential interaction between atypical antipsychotic medications and several hormones known to influence appetite regulation and carbohydrate metabolism.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18261494     DOI： 10.1016/j.amjmed.2007.08.036

Source DB:  PubMed          Journal:  Am J Med        ISSN： 0002-9343            Impact factor:   4.965


  8 in total

1.  Oral bioavailability and brain penetration of (-)-stepholidine, a tetrahydroprotoberberine agonist at dopamine D(1) and antagonist at D(2) receptors, in rats.

Authors:  Yan Sun; Jieyu Dai; Zheyi Hu; Feifei Du; Wei Niu; Fengqing Wang; Fei Liu; Guozhang Jin; Chuan Li
Journal:  Br J Pharmacol       Date:  2009-09-25       Impact factor: 8.739

2.  Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulation.

Authors:  Yvette E Savoy; Michael A Ashton; Matthew W Miller; Frank M Nedza; Douglas K Spracklin; Mark H Hawthorn; Hans Rollema; F Fatima Matos; Eva Hajos-Korcsok
Journal:  Schizophr Bull       Date:  2008-08-14       Impact factor: 9.306

3.  Dopamine-mediated autocrine inhibitory circuit regulating human insulin secretion in vitro.

Authors:  Norman Simpson; Antonella Maffei; Matthew Freeby; Steven Burroughs; Zachary Freyberg; Jonathan Javitch; Rudolph L Leibel; Paul E Harris
Journal:  Mol Endocrinol       Date:  2012-08-21

4.  Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors.

Authors:  Despoina Aslanoglou; Suzanne Bertera; Marta Sánchez-Soto; R Benjamin Free; Jeongkyung Lee; Wei Zong; Xiangning Xue; Shristi Shrestha; Marcela Brissova; Ryan W Logan; Claes B Wollheim; Massimo Trucco; Vijay K Yechoor; David R Sibley; Rita Bottino; Zachary Freyberg
Journal:  Transl Psychiatry       Date:  2021-02-16       Impact factor: 6.222

5.  Successful treatment of hyperglycemia with liraglutide in a hospitalized 27-year-old patient with schizophrenia: A case report.

Authors:  Lei Zhang; Wen-Juan Yu; Hui Zhu; Hua-Fang Li; Jie Qiao
Journal:  World J Clin Cases       Date:  2022-07-26       Impact factor: 1.534

6.  Weight gain, schizophrenia and antipsychotics: new findings from animal model and pharmacogenomic studies.

Authors:  Fabio Panariello; Vincenzo De Luca; Andrea de Bartolomeis
Journal:  Schizophr Res Treatment       Date:  2010-12-06

7.  Alstonine as an antipsychotic: effects on brain amines and metabolic changes.

Authors:  Viviane M Linck; Ana P Herrmann; Angelo L Piato; Bernardo C Detanico; Micheli Figueiró; Jorge Flório; Maurice M Iwu; Christopher O Okunji; Mirna B Leal; Elaine Elisabetsky
Journal:  Evid Based Complement Alternat Med       Date:  2011-06-23       Impact factor: 2.629

8.  Negative Correlation between Serum S100B and Leptin Levels in Schizophrenic Patients During Treatment with Clozapine and Risperidone: Preliminary Evidence.

Authors:  Narjes Hendouei; Seyed Hamzeh Hosseini; Amin Panahi; Zahra Khazaeipour; Fatemeh Barari; Adeleh Sahebnasagh; Shahram Ala
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.